1. Home
  2. DKI vs PPBT Comparison

DKI vs PPBT Comparison

Compare DKI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

N/A

Current Price

$0.39

Market Cap

6.2M

Sector

N/A

ML Signal

N/A

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.68

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
PPBT
Founded
2018
2010
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
6.5M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
DKI
PPBT
Price
$0.39
$0.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
129.1K
697.7K
Earning Date
02-11-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
26.19
N/A
Revenue
$10,204,329.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.01
N/A
Revenue Growth
100.46
N/A
52 Week Low
$0.30
$0.53
52 Week High
$15.00
$4.55

Technical Indicators

Market Signals
Indicator
DKI
PPBT
Relative Strength Index (RSI) N/A 44.60
Support Level N/A $0.64
Resistance Level N/A $0.68
Average True Range (ATR) 0.00 0.04
MACD 0.00 -0.00
Stochastic Oscillator 0.00 50.48

Price Performance

Historical Comparison
DKI
PPBT

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: